Health Catalyst (NASDAQ:HCAT) Releases Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Health Catalyst (NASDAQ:HCAT - Get Free Report) issued its quarterly earnings results on Wednesday. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by ($0.03), Briefing.com reports. The company had revenue of $76.40 million for the quarter, compared to analyst estimates of $76.27 million. Health Catalyst had a negative return on equity of 7.49% and a negative net margin of 26.20%. The company's quarterly revenue was up 3.5% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.22) EPS. Health Catalyst updated its FY 2024 guidance to EPS and its Q4 2024 guidance to EPS.

Health Catalyst Trading Down 7.0 %

NASDAQ:HCAT traded down $0.62 on Friday, reaching $8.24. 674,743 shares of the stock traded hands, compared to its average volume of 485,899. Health Catalyst has a 1-year low of $5.42 and a 1-year high of $11.41. The company's 50 day moving average is $8.07 and its 200-day moving average is $7.14. The firm has a market capitalization of $498.27 million, a price-to-earnings ratio of -6.10 and a beta of 1.32.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on HCAT shares. Stephens reduced their price objective on shares of Health Catalyst from $8.00 to $7.00 and set an "equal weight" rating on the stock in a research note on Thursday, August 8th. Royal Bank of Canada lifted their price target on Health Catalyst from $8.00 to $9.00 and gave the company a "sector perform" rating in a research note on Thursday. JPMorgan Chase & Co. raised their price objective on Health Catalyst from $10.00 to $13.00 and gave the company an "overweight" rating in a research note on Wednesday, September 4th. Cantor Fitzgerald reissued an "overweight" rating and set a $16.00 target price on shares of Health Catalyst in a research note on Friday, October 4th. Finally, Piper Sandler reduced their price target on shares of Health Catalyst from $14.00 to $11.00 and set an "overweight" rating on the stock in a research note on Monday, August 26th. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, Health Catalyst presently has an average rating of "Moderate Buy" and a consensus target price of $11.64.

Insider Transactions at Health Catalyst

In other news, insider Kevin Lee Freeman sold 7,500 shares of the stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total transaction of $54,150.00. Following the completion of the sale, the insider now directly owns 255,881 shares in the company, valued at $1,847,460.82. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other news, insider Kevin Lee Freeman sold 7,500 shares of Health Catalyst stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total value of $54,150.00. Following the completion of the sale, the insider now owns 255,881 shares in the company, valued at $1,847,460.82. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Daniel Lesueur sold 5,209 shares of the business's stock in a transaction dated Thursday, October 3rd. The shares were sold at an average price of $7.68, for a total value of $40,005.12. Following the completion of the sale, the chief operating officer now directly owns 134,899 shares of the company's stock, valued at $1,036,024.32. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 35,396 shares of company stock worth $266,280. Company insiders own 2.50% of the company's stock.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.